Bioporto A/S

Capital Structure and Liquidity Bioporto A/S maintains a strong liquidity position with a current ratio of 3.25, indicating the company can cover its short-term obligations more than three times over. The company's cash and equivalents amount to 54,893,000 DKK, which is significantly higher than its total liabilities of 30,173,000 DKK. Despite this, the company reported negative operating cash flow of -77,066,000 DKK, reflecting ongoing operational challenges. ### Profitability and Returns The company's profitability is underperforming, with a return on equity of -1.3033 and a return on assets of -0.8813, both significantly below industry norms. Operating income was -86,094,000 DKK, and net income was -82,117,000 DKK, indicating substantial losses. These figures suggest the company is struggling to generate returns on its equity and assets. ### Segments and Geographic Exposure Bioporto A/S operates through several product categories, including NGAL tests, MBL ELISA kits, and monoclonal antibodies. The company's geographic exposure is not explicitly detailed in the provided data, but its operations are centered in Denmark. The lack of detailed geographic breakdown limits the assessment of regional risk and growth potential. ### Growth Trajectory Analysts expect a slight increase in revenue, with a mean estimate of 42,000,000 DKK for the upcoming period, compared to the last actual revenue of 40,287,000 DKK. However, the mean EBIT estimate of -63,112,000 DKK suggests continued operational losses. The company's growth trajectory remains uncertain due to its current financial performance. ### Risk Factors The company faces low liquidity and dilution risks, with no immediate filing-based flags detected. However, the negative operating and free cash flows indicate potential liquidity challenges in the future. The company has not issued any new shares recently, and there is no indication of dilution pressure in the near term. ### Recent Events Recent financial reports highlight the company's ongoing losses and negative cash flows. Analysts have set a mean price target of 1.75 DKK, with all estimates converging at this level, indicating limited upside potential.